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Abstract
The call of the editorial of the International Journal of Health Policy and Management regarding the “Need 
to talk about corruption in health systems” is spot on. However, the perceived difficulties of why this is so 
should be explored from an actor’s perspective, as they differ for government actors, donors and the research 
community. In particular, false dilemmas around definition problems should be demystified, including by 
building systematic bridges between the anti-corruption/integrity and health policy communities of practice. 
In addition, the focus on corruption in frontline health service delivery generating mainly problems of access to 
health, needs to be complemented with addressing sophisticated kickback schemes, nepotism, and state capture 
of legislative and regulatory agencies and processes draining the health systems of large amounts of resources 
leading to another false dilemma of assumed sector underfunding. In terms of what can be done, comprehensive 
corruption experience and risk assessments conducted by independent actors, eg, universities, aimed at 
generating some basic consensus among the different actors of priority areas to be addressed on the basis of a 
co-responsibility approach could provide the basis for reform. Finally, governments and private sector actors 
in countries characterized by systemic corruption and clientelistic political systems will not reform themselves 
without strong and sustained demand from civil society and the media. 
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The call of the editorial of the International Journal of Health Policy and Management regarding the “Need to talk about corruption in health systems” is spot on.1 As 
explained in the editorial, corruption in health systems costs 
lives, not only by impeding access to life-saving treatments 
but also by killing people through the use of counterfeit or 
sub-standard drugs, eg, it impedes equitable access to quality 
care, it violates basic human rights, it undermines state 
legitimacy and trust in the health sector (both public and 
private), and it contributes to a possibly false dilemma of an 
assumed underfunding of the health sector. But there are 
estimates that allow to launch the hypothesis that if corruption 
in its multiple forms in the health sector was controlled, 
large part of the supposed underfunding could or would be 
resolved “Globally, over 7% of healthcare expenditure is lost 
to corruption. With annual global health expenditures  now 
exceeding US$7.5 trillion, this suggests that far over US$500 
billion in health resources are lost to corruption worldwide 
every year. Thus, curbing corruption in the sector could free 
up enough resources to pay for universal health coverage 
worldwide.”2
It is indeed surprising that despite an ever increasing 
body of evidence of the problem of corruption in health 
systems around the world – as revealed in international and 
a myriad of national perception surveys, corruption reports 
registered through the Anti-corruption Legal Advice Centers 
of Transparency International,3,4 incessant media reports on 
corruption scandals all over the world, including in relatively 
authoritarian regimes,5 a growing academic literature on 
corruption in the health sector, and persistent and publically 
reported corruption cases affecting the multimillion donor 
health programmes (bilateral, multilateral as well as vertical 
programmes) – the health policy community continues to 
have difficulties in many contexts to talk about corruption 
in health systems openly, frankly and with no fear of 
repercussions. 
Given the multiplicity of actors involved in the health sector, 
as well as their different legitimate institutional roles, dynamics 
and (dis-)incentives, it might be useful to distinguish the 
exploration for the reasons of why this is so according to the 
nature of the different actors,6 and I will do the same for the 
suggestions of potential remedies. Some of the reasons may 
apply to several actors but others will influence the behavior 
of one particular actor while not the other. For example, in 
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many countries it is difficult to use the term “corruption” as 
such in discussions with public sector officials or the political 
leadership. The term is often associated with gross crimes 
and nobody wants to be “titled” as being corrupt, which is 
often synonymous to being a criminal, and much less so when 
the corrupt practices in question err on the side of unethical 
behavior or administrative misconduct. On the other hand, 
for academic research it is usually not a great problem to 
use the term “corruption.” But for academics the definition 
problems might play a role when it comes to establishing a 
clear scope and focus of the research in question. Another 
example: the issues of “how do we conduct research on 
corruption in ways that capture what is really happening?” 
or “is it even legitimate to study corruption?” seem to be an 
impediment for researchers to talk about corruption. For 
government actors in-country one potential impediment 
lies in the fact that the institutional responsibility to develop, 
coordinate, and monitor anti-corruption policies usually lie 
with specialized central-government bodies, such as anti-
corruption agencies, transparency or integrity commissions 
who manage the terminology and definitions of corruption,7 
while health sector institutions tend to speak about 
irregularities and inefficiencies in particular. And on the side 
of donor agencies, reasons why there is little discussion about 
corruption in the health sector might include the perceived 
dilemma that open talks can have negative repercussions in the 
willingness to continue to invest in the sector (an aspect has 
been experienced by the author and colleagues in numerous 
occasions of anti-corruption on the health sector in countries 
from Afghanistan, through Cambodia, Ecuador, South Sudan 
to Zambia). Or in case that their sector counterparts do not 
address the issue in political and technical dialogues, donors 
tend to be reticent in pushing the issue given its political 
connotations and the fear of losing or damaging relationships 
that are crucial for programme implementation. 
In addition to the before, it would be useful to explore the 
perceived difficulties around the definition of corruption in 
order to demystify some of them, something which might 
be achieved by building more systematic bridges between 
the anti-corruption/integrity and health policy communities 
of practice. In this sense, it is important to highlight 
that corruption encompasses a broad range of practices 
spanning from unethical behaviors, through administrative 
misdemeanors to outright criminal offences. In most 
countries, there is broad acceptance of what constitutes 
criminal offences and mostly administrative misconduct. 
Kickback schemes in procurement, insurance fraud, 
embezzlement of funds and diversion of budget transfers 
from one administrative level to another, position buying and 
selling, stealing of equipment, ambulances, etc are straight 
forward administrative, fiscal and/or penal crimes and 
therefore should not constitute definitional problems to talk 
about. On the other hand, ethical misconduct and behaviors 
that might be widely accepted although they are against 
the law, such as informal payments, absenteeism, etc are 
issues that require context specific analysis, discussion and 
agreement on how to deal with them, both from the policy 
and management perspective. Although all of these behaviors 
would classify as corruption, and do so in many countries, it 
is not the same to label a nurse or medical doctor involved in 
these types of “frontline” corruption with the same “corruption 
stigma” as the director of procurement of the national drug 
store who might be siphoning off hundreds of thousands of 
dollars through fraudulent drug procurement. Hence, one 
challenge to promote open discussion about corruption in 
the health sector is to develop clear language or terminologies 
on the different forms of corruption: from a research, from 
a public policy and from a public management perspective 
acknowledging the differences of impact, while avoiding to 
fall into an unhealthy “corruption relativism.” 
Finally, there are a few enigmas in the health policy 
community when it does address corruption: on the one hand, 
the spotlight seems to be mainly shed on what can is often 
called “petty corruption” or corruption in frontline health 
service delivery, including informal payments, absenteeism, 
dual practice, inducement for unnecessary treatment, and 
there is a relatively broad body of literature on these issues. 
However, the types of corruption like sophisticated kickback 
schemes, serious conflicts of interest of high-level policy, 
regulatory and management officials, nepotism, and state 
capture of legislative and regulatory agencies and processes 
does not seem to get similar attention.8 While these types of 
corruption are more difficult to be captured in opinion and 
experience surveys, it is less understandable why there is 
relatively little documented experience or research although 
these, often criminal, forms of corruption have an enormous 
impact on the overall health system functioning as well as the 
available financial resources.9 
Now, the question of what can or should be done, or which 
strategies can be pursued to get the different actors to talk 
about corruption in health systems: Similar to identifying the 
reasons of why there is a considerable silence on the issues, 
it would be useful to define different strategies for different 
actors taking into account their roles, dynamics, incentives as 
well as constraints. 
Thus at country-level, in an ideal case scenario a 
comprehensive health sector corruption assessment would 
be carried out, focusing on both concrete experiences 
(where possible) as well as risks of corruption and would 
encompass the national level as well as a selection of sub-
national level regions.10 Such an assessment would ideally be 
conducted by a well-respected university under the auspices 
of but independent from the health sector lead authorities 
(Minister of Health, Director of Health Insurance, Director of 
Superintendency, Director of Drug and Food Regulatory Body, 
etc). This first step of producing the necessary evidence is an 
excellent opportunity for donor support as many countries 
struggle to assign the necessary budget to such an activity. 
The results will provide inputs  to convene key stakeholders 
of the whole system, discuss openly the problems and define 
jointly solutions. This generation of a political consensus in a 
particular country for the definition of priorities must include 
not only public sector actors but also those from the private 
sector, be it pharmaceutical or medical device companies, 
healthcare providers or private insurers.11 The definition 
of a concrete road map to address the different prioritized 
problems is crucial and will require context specific analysis 
of political economy in order to navigate with and through 
the powerful interest. An ensuing action plan with objectives 
should reflect ideally progress related with sector goals and 
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to the extent possible health outcomes, while some indicators 
on increased access to information or accountability or the 
management of conflicts of interest, eg, might be useful 
complementary monitoring elements. It might be useful 
to foster inter-institutional coordination between health 
sector public entities and the respective anti-corruption or 
transparency body in order to feed into the national cross-
cutting anti-corruption policies and public discourse. The 
latter could be particularly useful if there were additional 
elements of traction, such as international commitments, eg, 
the Open Government Partnership,12 the Public Contracting 
Partnership, regional or international conventions, the 
Sustainable Development Goals, etc. 
With regard to the research community, in addition to 
the important suggestions of the editorial  to promote inter-
disciplinary research, academia can play an role to provide 
more insight on what works, what does not and under what 
conditions from perspective of more comparative research.13 
Although corruption and in particular the mitigating 
measures are highly context specific, comparative research 
could help to offer inspirations, avoid pitfalls and prevent 
the need for reinventing the wheel. In addition, the research 
community could make an extremely relevant contribution 
to the field by producing more research on the “higher level” 
types of corruption, including policy and regulatory capture, 
conflicts of interest in high decision-making positions, the 
pharmaceutical value chain as well as their system-wide 
impact in terms of access to health but in particular on the 
financial sustainability of the system. And finally, the research 
community could support the health policy community by 
producing political economy and drivers of change analysis 
focused on the health sector but embedding this in the 
broader country context. 
As for the donor community, despite increasing recognition 
of the problems and certain action taken to address them, there 
is ample room for improvement. The health and governance/
anti-corruption units and experts of each donor should 
interact much more systematically both at headquarters and 
in country; inter-donor coordination in the field around 
corruption and anti-corruption approaches should be more 
explicit and at least minimally resourced; donors should 
provide regular support for the generation of country-level 
analysis to help provide inputs for rational national debates 
and policy-making. And in addition to supporting public 
sector reform, donors should provide funding, technical and 
“political” support to civil society organizations in view of 
strengthening demand for and monitoring of transparency 
and integrity approaches. The recently started initiative by 
the World Health Organization, United Nations Development 
Programme, and the Global Fund to create a Global Network 
on Anti-corruption, Transparency and accountability is a 
further and promising step to contribute to generating much 
needed evidence and coordination.14 
Finally, governments and private sector actors in countries 
characterized by systemic corruption and clientelistic 
political systems will not reform themselves without strong 
and sustained demand from civil society and the media. 
If transformational change is to be achieved, it is key to 
strengthen these actors, build bridges and alliances between 
specific health sector organizations and governance or 
integrity promoting civil society organizations, work with 
journalists and media companies and develop strategies that 
will allow to sustain demand for reform through government 
changes as well as help avoid backsliding on progress made. 
As stated in the editorial, a wider conversation about 
corruption in the health sector and how to address it is direly 
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